Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, Nouscom Ink Cell Line Platform Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

ProBioGen, Nouscom Ink Cell Line Platform Pact

Nouscom licenses AGE1.CR duck retina cell line for production of its viral vectored vaccine

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Nouscom AG have signed a license agreement giving Nouscom access to ProBioGen’s production platform based on the AGE1.CR duck retina cell line for production of its viral vectored vaccines.

Dr. Volker Sandig, ProBioGen’s chief scientific officer, said, “We have developed the AGE1.CR® designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom´s highly innovative vaccine approach will greatly benefit from it.”

Nouscom’s chief technology officer, Dr. Stefano Colloca added, “We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics